Lavinia Davidescu, EAACI Digital Congress 2020 – Masitinib for Severe Persistent Asthma
Following an excellent presentation at the EAACI Digital Congress 2020, we caught up with Lavinia Davidescu (University of Oradea, Romania). We discussed the findings from the phase 3 study of masitinib in the treatment of patients with severe persistent asthma (NCT01449162) and what the future holds.
Questions
1. Could you tell us a little about masitinib and its mechanism of action? (0:04)
2. Could you give us an overview of Study AB07015 and its major efficacy and safety findings? (1:24)
3. What were the findings of the subgroup analysis in eosoniphilic asthma patients, and what are the implications of these findings? (04:29)
4. What future studies are planned? (11:26)
Speaker disclosure: Lavinia Davidescu is the coordinating investigator of masitinib study AB07015 in severe asthma uncontrolled with oral corticosteroids.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EAACI Digital Congress 2020.
